Skip to content

Author

Biswajit Mandal

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Targeting EZH2 and EGFR Therapeutic Vulnerabilities of TNBC with a Single Chemical Entity Confers Preclinical Treatment Advantage.

Globally, Triple-Negative Breast Cancer (TNBC) has huge unmet medical need as it has limited targeted therapeutic options. However, it has well-known therapeutic vulnerabilities for selective inhibition of pathways like EGFR, m-TOR, PARP, EZH2, PD1-PDL1 etc. Analysis of publicly available databases clearly suggest that...

Saumya Ranjan Satrusal, Arpita Banerjee, Arpon Biswas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.